📈

Amgen Inc.

AMGNDividend Contender • 14yrs
Healthcare · Drug Manufacturers - General🇺🇸 United States
$439.26
Dividend Yield2.29%
Annual Dividend$10.08
Ex-Dividend DateAug 21, 2026
Market Cap$233.82B
60/ 100
Financial Health
Stable
⚠ Heavy leverage (D/E 4.9x)Strong ROE (91%)Revenue growing (10%)

Automated dividend-safety read-out from payout, leverage, yield, profitability and track record. See the Financials tab for the full per-statement Financial Investigation. Educational only — not investment advice.

At a glance

Amgen Inc. (AMGN) operates in the Drug Manufacturers - General industry and is based in the United States. It pays a quarterly dividend of $10.08 a year, a yield of 2.29% at the current price of $439.26. Amgen has raised its dividend for 14 consecutive years, which makes it a Dividend Contender. Over the last five years the dividend has grown by an average of 8.3% a year. It paid out 61% of its earnings as dividends. 34 analysts cover it; their average 12-month price target of $394.98 is 10.1% below the current price.

Written automatically from the figures on this page, as of Oct 24, 2026. Facts only, not a recommendation.

Price History
Dividend payment dates
Analyst Consensus
Hold
Bullish sentiment
35% of 34 analysts bullish
12-Month Price Target
$394.98
-10.1% vs current price

About Amgen Inc.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Business description sourced from Yahoo Finance / company filings. Not affiliated with SimplyWallStreet.

Key Metrics

Valuation

P/E Ratio
26.9
P/B Ratio
20.00
EV/EBITDA
16.0
Beta
0.41
vs S&P 500
52W High
$447.03
52W Low
$288.00

Profitability

Gross Margin
71.89%
Operating Margin
35.55%
Net Margin
22.95%
ROE
91.47%
Free Cash Flow
$8.65B

Financial Health

Debt / Equity
490.28
lower is safer
Current Ratio
1.37
>1 healthy
Quick Ratio
0.95
>1 healthy
Employees
31,500
HQ
Thousand Oaks, CA, United States
Data: Yahoo Finance (yfinance)|Updated: Oct 24, 2026 11:38

Data provided by Yahoo Finance via yfinance. Updated daily. Not investment advice.

Legal Disclaimer

This website is not a financial advisor, investment advisor, or financial services provider. We do not offer, recommend, or imply any investment advice of any kind. We do not receive compensation, commissions, or any other benefit from any company, fund, financial product, or third party featured on this site. No content on this website constitutes a recommendation or solicitation to buy, sell, or hold any security or financial instrument.

All financial analysis, ratios, and written commentary are provided for educational and informational purposes only. The Financial Analysis and Financial Investigation sections reflect automated computations applied to publicly available financial data — they do not represent the opinion of a licensed financial professional. Always conduct your own independent research and consult a qualified, regulated financial adviser before making any investment decision. Past performance of dividends, prices, or earnings is not a guarantee of future results.

Data Sources: Yahoo Finance via yfinance (real-time prices, dividend history, financial statements, analyst ratings and price targets) · S&P 500 Dividend Aristocrats Index (official constituent list) · Dividend Kings public records (companies with 50+ years of consecutive dividend increases) · SEC EDGAR company filings (10-K annual reports — primary source for all financial statement data). Data is fetched automatically each day and may be delayed up to 24 hours. All figures are in USD unless otherwise stated.